About 1,500 patients expected to benefit from risdiplam, which can be taken as syrup at home
The NHS is to introduce a revolutionary new treatment to tackle the leading genetic cause of death among babies and young children.
About 1,500 patients in England with certain types of spinal muscular atrophy (SMA) are expected to benefit from risdiplam, after a recommendation from the health watchdog. The drug, also called Evrysdi and made by Roche, is a syrup that can be taken at home and is the first non-injectable treatment for the condition.
